(Q50883727)

24 March 2018

review article

1 reference

title

DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. (English)

1 reference

24 March 2018

1 reference

5

Simard J

1 reference

24 March 2018

Labrie F

1

1 reference

24 March 2018

Bélanger A

2

1 reference

24 March 2018

Luu-The V

3

1 reference

24 March 2018

Labrie C

4

1 reference

24 March 2018

Cusan L

6

1 reference

24 March 2018

Gomez JL

7

1 reference

24 March 2018

Candas B

8

1 reference

24 March 2018

publication date

1 May 1998

1 reference

24 March 2018

published in

Steroids

1 reference

24 March 2018

volume

63

1 reference

24 March 2018

page(s)

322-328

1 reference

24 March 2018

issue

5-6

1 reference

24 March 2018

Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

1 reference

7 January 2021

Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

DHEA and peripheral androgen and estrogen formation: intracinology

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Radioimmunoassay of 17β-hydroxy-5α-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17-hydroxyprogesterone and progesterone and its application to human male plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Inhibition of tumor development by dehydroepiandrosterone and related steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

What do we know and what don't we know about tamoxifen in the human uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Comparison of pharmacodynamic properties of various estrogen formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-128X%2898%2900007-5

7 January 2021

10.1016/S0039-128X(98)00007-5

Identifiers

DOI

1 reference

24 March 2018

release_gxp54bmvpfcxbgpnxszlevu2vm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gxp54bmvpfcxbgpnxszlevu2vm

24 November 2022

mapped directly with Wikidata item

PubMed ID

9618795

1 reference

24 March 2018